[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651170":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":34,"collaborators":38,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Sohag University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Breast cancer female patients",null,"Female patients with histopathologically confirmed breast cancer diagnosed at Sohag Oncology center during 2025-2026. Archived formalin-fixed paraffin-embedded tissue samples and pathology records will be retrospectively reviewed to evaluate HER2 status by immunohistochemistry (IHC)",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Dr. Fatma El-Zahraa Prof. Dr. Fatma El-Zahraa Salah El-Deen Safe El-Deen, Professor of Pathology","CONTACT","01007970144","fatmafm2002@yahoo.com",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Dr. Ola Dr. Ola Mohamed Nageeb Mazeed, Lecturer of Pathology","01005156672","Olaamohamed@med.sohag.edu.eg",[23],{"facility":24,"status":10,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":10},"Faculty of medicine sohag university","Sohag","Egypt","EG",{"type":29,"coordinates":30},"Point",[31,32],31.69478,26.55695,{"lat":32,"lon":31},{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Rana Amgad Anwar","Pathology resident at Sohag Oncology Center",[39],{"name":40,"class":41},"Sohag Oncology Center","OTHER_GOV","100651170","updates-and-insights-on-her2-in-breast-cancer-in-sohag-governorate-100651170",false,"NCT07758127","Updates and Insights on HER2 in Breast Cancer in Sohag Governorate","Updates and Insights on Human Epidermal Growth Factor Receptor 2 (HER2) in Breast Cancer in Sohag Governorate","HER2","Inclusion Criteria:\n\n* Breast cancer cases diagnosed during 2025 and 2026.\n* Cases with available HER2 immunohistochemical results.\n* Cases with sufficient tissue material for evaluation.\n* Cases with complete clinical and follow-up data.\n* Cases that were accessible for pathologic review\n\nExclusion Criteria:\n\n* Cases with insufficient, destroyed, necrotic, or unavailable tissue blocks.\n* Cases with incomplete clinical information.\n* Cases lacking adequate immunohistochemical assessment.\n* Cases outside the study period","FEMALE","26 Years","85 Years",{"count":54,"type":55},100,"ESTIMATED","OBSERVATIONAL","* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.\n* To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes\n* To access interobserval agreement in HER2 score interpretation",[59],"HER2 Status in Breast Cancer",[48],"NOT_YET_RECRUITING","2026-08-10",{"date":64,"type":65},"2026-08-12","ACTUAL",{"date":67,"type":55},"2026-09",{"date":69,"type":55},"2027-12",{"name":5,"class":6},1]